How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease? (Q26777409)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?	scientific article

Statements

scholarly article

0 references

How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease? (English)

0 references

inflammatory bowel diseases

0 references

2

object named as

Peter M Irving

0 references

author name string

Mark G Ward

1

0 references

Miles P Sparrow

3

0 references

language of work or name

0 references

publication date

28 October 2015

0 references

World Journal of Gastroenterology

0 references

21

0 references

40

0 references

11331-42

0 references

Management of inflammatory bowel disease in pregnancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

7 April 2017

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

7 April 2017

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

7 April 2017

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

7 April 2017

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

7 April 2017

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

7 April 2017

Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Review article: explaining risks of inflammatory bowel disease therapy to patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

28 September 2017

Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

31 May 2018

Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

31 May 2018

Increased Risk of Nonmelanoma Skin Cancers Among Individuals With Inflammatory Bowel Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

31 May 2018

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

31 May 2018

Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

31 May 2018

Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4616209

31 May 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Ten years of infliximab for Crohn's disease: outcome in 469 patients from 2 tertiary referral centers

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab.

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Restaurantmanhaj's

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD.

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC.

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort.

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Methotrexate for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I40.11331

21 January 2018

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26525434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab for Crohn's disease: long-term sustained benefit in a population-based cohort of 438 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26525434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab dose intensification in Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26525434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heading back to the trough (levels of biologics in IBD)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26525434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26525434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26525434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26525434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine

1 reference

https://pubmed.ncbi.nlm.nih.gov/26525434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26525434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3748/WJG.V21.I40.11331

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26777409&oldid=2262740543"